UPDATED: OncoMed hits the brakes on PhII pancreatic cancer trial, shares plummet

John Carroll

slammed the on a Phase II study of the stem cell drug tarextumab, citing worsening response rates in the drug arm for , with red flags shooting up for overall survival as well as progression-free survival rates among patients.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS